ONCR Oncorus, Inc.

Oncorus, Inc. engages in the research and development of viral immunotherapies platform. It develops immunotherapy platform to treat cancer such as oncolytic Herpes Simplex Virus Platform and Synthetic Virus Platform. The company was founded by Mitchell H. Finer, Joseph C. Glorioso III, Kenneth P. Greenberg, Cyrus D. Mozayeni, and Paola Grandi on April 1, 2015 and is headquartered in Cambridge, MA.

$5.65
As of 12/03/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/01/2020
Outstanding shares:  25,809,006
Average volume:  455,513
Market cap:   $149,950,325
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    68236R103
ISIN:        US68236R1032
Sedol:      BKX9NM6
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.98
PS ratio:   0.00
Return on equity:   -38.21%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy